TNDM
Tandem Diabetes Care, Inc. NASDAQ Listed Nov 14, 2013$15.30
-0.65%
vs $15.40
Mkt Cap $1.0B
52w Low $10.12
28.6% of range
52w High $28.26
50d MA $17.63
200d MA $18.53
P/E (TTM)
-5.0x
EV/EBITDA
—
P/B
6.6x
Debt/Equity
2.9x
ROE
-0.4%
P/FCF
-34.7x
RSI (14)
41.00
ATR (14)
$1.25
Beta
1.74
50d MA
$17.63
200d MA
$18.53
Avg Volume
3.0M
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
11075 Roselle Street · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.46 | -0.30 | +34.8% | 18.47 | +8.3% | -16.2% | -4.6% | -0.5% | -3.9% | +0.3% | — |
| Feb 19, 2026 | AMC | -0.05 | -0.01 | +80.0% | 18.52 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% | — |
| Nov 6, 2025 | AMC | -0.31 | -0.31 | +0.0% | 13.33 | +20.0% | +22.0% | +0.7% | +7.0% | +3.1% | -2.9% | — |
| Aug 6, 2025 | AMC | -0.40 | -0.48 | -20.0% | 14.39 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% | — |
| Apr 30, 2025 | AMC | -0.60 | -0.67 | -11.7% | 16.85 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% | — |
| Feb 26, 2025 | AMC | -0.25 | -0.44 | -76.0% | 33.59 | -28.0% | -35.2% | +1.8% | -6.1% | -6.2% | -1.9% | — |
| Nov 6, 2024 | AMC | -0.43 | -0.36 | +16.3% | 34.24 | -4.8% | -2.7% | -8.2% | +2.5% | -0.9% | -4.6% | — |
| Aug 1, 2024 | AMC | -0.54 | -0.47 | +13.0% | 35.21 | +17.2% | +18.3% | -2.1% | +6.4% | -14.6% | -0.4% | — |
| May 2, 2024 | AMC | -0.80 | -0.63 | +21.2% | 36.56 | +17.4% | +22.3% | -2.7% | +1.1% | -4.2% | +4.5% | — |
| Feb 21, 2024 | AMC | -0.23 | -0.27 | -17.4% | 22.55 | +8.6% | +10.9% | +16.5% | -0.9% | -5.3% | -2.8% | — |
| Nov 1, 2023 | AMC | -0.35 | -0.38 | -8.6% | 17.75 | -11.3% | -14.4% | +3.6% | -2.8% | +6.2% | -4.6% | — |
| Aug 3, 2023 | AMC | -0.54 | -0.30 | +44.4% | 31.99 | -6.6% | +4.4% | -9.8% | -6.6% | +1.7% | +2.4% | — |
| May 3, 2023 | AMC | -0.56 | -0.63 | -12.5% | 39.95 | -11.9% | -6.1% | -6.5% | -4.6% | -2.2% | +1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 1 | Wells Fargo | Upgrade | Equal Weight → Overweight | $27 | $17.20 | $19.47 | +13.2% | +11.2% | -2.7% | -3.1% | +7.9% | -0.6% |
| May 12 | The Benchmark Company | Initiates | Hold | — | $14.77 | $14.74 | -0.2% | -0.5% | -3.9% | +0.3% | -9.4% | +5.5% |
| Apr 20 | TD Cowen | Maintains | Buy → Buy | — | $20.61 | $20.88 | +1.3% | +3.1% | -5.7% | +3.7% | -0.5% | -1.5% |
| Apr 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.35 | $19.34 | -0.1% | +1.7% | -2.5% | +4.8% | +5.0% | -2.1% |
| Mar 19 | Truist | Upgrade | Hold → Buy | — | $23.85 | $25.04 | +5.0% | +3.3% | +0.8% | +1.1% | -2.3% | -1.0% |
| Mar 17 | Piper Sandler | Upgrade | Neutral → Overweight | — | $21.91 | $23.16 | +5.7% | +9.1% | -0.3% | +3.3% | +0.8% | +1.1% |
| Mar 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.30 | $24.88 | -1.7% | -0.3% | -5.9% | -1.4% | -3.3% | -6.6% |
| Feb 23 | Lake Street | Upgrade | Hold → Buy | — | $24.57 | $25.59 | +4.2% | +15.0% | -4.8% | -3.3% | -0.8% | -1.9% |
| Feb 23 | Truist | Maintains | Hold → Hold | — | $24.57 | $25.59 | +4.2% | +15.0% | -4.8% | -3.3% | -0.8% | -1.9% |
| Feb 20 | Piper Sandler | Maintains | Neutral → Neutral | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 20 | BofA Securities | Upgrade | Underperform → Neutral | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 20 | UBS | Maintains | Neutral → Neutral | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 20 | Stifel | Maintains | Hold → Hold | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 20 | Mizuho | Maintains | Neutral → Neutral | — | $18.52 | $22.75 | +22.8% | +32.7% | +15.0% | -4.8% | -3.3% | -0.8% |
| Feb 4 | Stifel | Maintains | Hold → Hold | — | $19.44 | $19.44 | +0.0% | -2.3% | -0.3% | +1.2% | -1.5% | +3.4% |
| Jan 9 | Bernstein | Maintains | Market Perform → Market Perform | — | $22.50 | $23.03 | +2.4% | -3.6% | -1.6% | -2.1% | -0.1% | +1.0% |
| Dec 18 | Truist | Maintains | Hold → Hold | — | $22.42 | $22.44 | +0.1% | -2.8% | +1.2% | +5.4% | -2.8% | -0.6% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $22.60 | $22.67 | +0.3% | -0.8% | -2.8% | +1.2% | +5.4% | -2.8% |
| Dec 17 | Mizuho | Maintains | Neutral → Neutral | — | $22.60 | $22.67 | +0.3% | -0.8% | -2.8% | +1.2% | +5.4% | -2.8% |
| Dec 16 | Baird | Upgrade | Neutral → Outperform | — | $22.11 | $24.46 | +10.6% | +2.2% | -0.8% | -2.8% | +1.2% | +5.4% |
| Dec 11 | Citigroup | Maintains | Neutral → Neutral | — | $21.45 | $20.78 | -3.1% | -2.2% | +2.0% | +3.4% | +2.2% | -0.8% |
| Dec 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $20.51 | $20.73 | +1.1% | -4.3% | +1.6% | +3.9% | +1.0% | -0.9% |
| Nov 10 | Truist | Maintains | Hold → Hold | — | $16.26 | $16.51 | +1.5% | +0.7% | +7.0% | +3.1% | -2.9% | +6.2% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $16.26 | $16.51 | +1.5% | +0.7% | +7.0% | +3.1% | -2.9% | +6.2% |
| Nov 10 | Barclays | Maintains | Overweight → Overweight | — | $16.26 | $16.51 | +1.5% | +0.7% | +7.0% | +3.1% | -2.9% | +6.2% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $13.33 | $16.00 | +20.0% | +22.0% | +0.7% | +7.0% | +3.1% | -2.9% |
| Oct 15 | Truist | Maintains | Hold → Hold | — | $14.38 | $14.52 | +1.0% | +2.6% | +3.7% | -3.3% | +5.1% | -1.0% |
| Oct 7 | Citigroup | Maintains | Neutral → Neutral | — | $15.01 | $15.14 | +0.9% | -3.3% | +5.6% | -3.4% | -5.5% | -0.9% |
| Sep 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $12.00 | $12.08 | +0.7% | -1.8% | +3.0% | +2.2% | +5.6% | +12.2% |
| Sep 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.58 | $12.59 | +0.1% | -0.6% | +0.5% | -1.5% | +3.4% | -4.1% |
| Aug 21 | Citigroup | Maintains | Neutral → Neutral | — | $10.68 | $10.56 | -1.1% | +3.5% | +8.0% | +1.5% | +1.1% | +0.1% |
| Aug 12 | Citigroup | Upgrade | Sell → Neutral | — | $10.12 | $11.07 | +9.4% | +9.8% | +0.2% | -4.2% | +1.5% | +0.2% |
| Aug 11 | Lake Street | Downgrade | Buy → Hold | — | $11.23 | $11.11 | -1.1% | -9.9% | +9.8% | +0.2% | -4.2% | +1.5% |
| Aug 8 | Barclays | Maintains | Overweight → Overweight | — | $11.52 | $11.65 | +1.1% | -2.5% | -9.9% | +9.8% | +0.2% | -4.2% |
| Aug 7 | UBS | Maintains | Neutral → Neutral | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Aug 7 | Piper Sandler | Downgrade | Overweight → Neutral | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Aug 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Aug 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.39 | $10.50 | -27.0% | -19.9% | -2.5% | -9.9% | +9.8% | +0.2% |
| Jul 9 | Citigroup | Downgrade | Neutral → Sell | — | $16.62 | $15.34 | -7.7% | -4.6% | +2.0% | -3.6% | +1.0% | -3.5% |
| May 22 | Citigroup | Maintains | Neutral → Neutral | — | $21.65 | $21.58 | -0.3% | -4.7% | +0.4% | +3.7% | -1.5% | +0.6% |
| May 1 | Stifel | Maintains | Buy → Buy | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| May 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| May 1 | Baird | Maintains | Neutral → Neutral | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| May 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.85 | $18.66 | +10.7% | +18.6% | +7.5% | -0.9% | +0.1% | +4.4% |
| Mar 5 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $19.49 | $19.18 | -1.6% | -1.9% | -2.0% | -4.1% | +1.1% | -1.5% |
| Mar 4 | Citigroup | Downgrade | Buy → Neutral | — | $20.78 | $20.00 | -3.8% | -6.2% | -1.9% | -2.0% | -4.1% | +1.1% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $22.14 | $21.83 | -1.4% | -6.1% | -6.2% | -1.9% | -2.0% | -4.1% |
| Mar 3 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $22.14 | $21.83 | -1.4% | -6.1% | -6.2% | -1.9% | -2.0% | -4.1% |
No insider trades available.
8-K · 5.02
!!! Very High
Tandem Diabetes Care, Inc. -- 8-K 5.02: Executive Change
May 15
8-K · 1.01
!! High
Tandem Diabetes Care, Inc. -- 8-K 1.01: Material Agreement
Tandem Diabetes Care issued convertible notes on February 27, 2026, providing capital for operations and potential acquisitions while giving investors conversion rights into company stock.
Feb 27
8-K
Tandem Diabetes Care, Inc. -- 8-K Filing
Tandem Diabetes Care reported Q4 and full-year 2025 financial results, providing 2026 guidance as a global insulin delivery company navigates ongoing market dynamics.
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 4,160,994 | $91M | Added | Dec 2025 |
| 2 | Vanguard Portfolio Management Llc | 3,993,333 | $77M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 3,038,919 | $58M | New | Mar 2026 |
| 4 | Jennison Associates Llc | 2,021,376 | $44M | Added | Dec 2025 |
| 5 | Citadel Advisors Llc | 2,192,667 | $42M | Added | Mar 2026 |
| 6 | Ubs Group Ag | 2,047,801 | $39M | Added | Mar 2026 |
| 7 | Paradice Investment Management Llc | 2,042,425 | $39M | Reduced | Mar 2026 |
| 8 | Two Sigma Investments, Lp | 1,864,194 | $36M | Added | Mar 2026 |
| 9 | Marshall Wace, Llp | 1,442,472 | $28M | Added | Mar 2026 |
| 10 | D.e. Shaw & Co | 783,906 | $15M | Reduced | Mar 2026 |
| 11 | Soleus Capital Management, L.p. | 783,000 | $15M | New | Mar 2026 |
| 12 | Defilade Capital Management, L.p. | 761,905 | $15M | New | Mar 2026 |
| 13 | Millennium Management | 761,672 | $15M | Added | Mar 2026 |
| 14 | Fmr Llc | 714,011 | $14M | Added | Mar 2026 |
| 15 | Northern Trust Corp | 706,609 | $14M | Added | Mar 2026 |
| 16 | Quantinno Capital Management Lp | 653,870 | $13M | Added | Mar 2026 |
| 17 | Frontier Capital Management Co Llc | 412,269 | $9M | Reduced | Dec 2025 |
| 18 | Aberdeen Group Plc | 434,027 | $8M | Reduced | Mar 2026 |
| 19 | Barclays Plc | 421,236 | $8M | Reduced | Mar 2026 |
| 20 | Point72 Asset Management | 420,478 | $8M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.03B
Enterprise Value
$1.16B
P/E (TTM)
-5.03x
Forward P/E
—
PEG Ratio
-0.07x
P/B
6.63x
P/S
1.01x
P/FCF
-34.70x
EV/EBITDA
—
Shares Out
67.3M
Financials (TTM)
Revenue
$1.01B
Net Income
-$204.7M
EBITDA
-$174.7M
Free Cash Flow
-$29.7M
Op Cash Flow
-$9.7M
EPS Basic
$-3.04
EPS Diluted
$-3.04
EPS Forward
$-0.76
Gross Margin
52.3%
Op Margin
-7.7%
Net Margin
-20.2%
Balance Sheet
Total Assets
$881.1M
Total Liab.
$725.9M
Total Equity
$155.2M
Cash
$292.7M
LT Debt
$425.0M
Book Value/Sh
$2.31
Debt/Equity
2.86x
Current Ratio
2.55
Quick Ratio
2.02
Returns & Growth
ROE
-0.4%
ROA
-0.1%
ROIC
-11.9%
Rev Growth YoY
+7.9%
EPS Growth YoY
-106.8%
Price Returns
2W
+21.6%
1M
-11.9%
3M
-32.0%
6M
-18.1%
12M
-13.2%
Technicals
52W High
$28.26
52W Low
$10.12
50d MA
$17.63
200d MA
$18.53
RSI (14)
41.00
ATR (14)
$1.25
Beta
1.74
Avg Volume
3.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$31.62
High
$56.00
Low
$21.00
Median
$28.00
Data updated apr 27, 2026 5:10am
· Source: financialmodelingprep.com